Scholarlink

<p>Colorectal cancer is one of the most common cancers in Germany among both sexes and is the leading cause of cancer-related mortality. In 2002, colonoscopy screening was introduced without sufficient evidence of its benefits. In many other European countries, sigmoidoscopy screening is preferred. In 2022, the first randomized study on colonoscopy screening was published: the benefits of colonoscopy screening are very low: participation does not affect overall mortality. New to the German S3 guideline are the recommendations for equal use of sigmoidoscopy, sequential screening using the immunochemical fecal occult blood test (iFOBT), and colonoscopy only in the case of a&#xa0;positive test—and as direct colonoscopy. Corresponding decision-making aids for consultation in general practice have been developed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Screening auf kolorektales Karzinom – was sagt die Evidenz?

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Günther Egidi,
  • Thomas Maibaum

摘要

Colorectal cancer is one of the most common cancers in Germany among both sexes and is the leading cause of cancer-related mortality. In 2002, colonoscopy screening was introduced without sufficient evidence of its benefits. In many other European countries, sigmoidoscopy screening is preferred. In 2022, the first randomized study on colonoscopy screening was published: the benefits of colonoscopy screening are very low: participation does not affect overall mortality. New to the German S3 guideline are the recommendations for equal use of sigmoidoscopy, sequential screening using the immunochemical fecal occult blood test (iFOBT), and colonoscopy only in the case of a positive test—and as direct colonoscopy. Corresponding decision-making aids for consultation in general practice have been developed.